Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
05/2003
05/30/2003WO2003043982A1 Derivatives of andrimide and moiramide b having antibacterial properties
05/30/2003WO2003043669A1 Composition and method for treatment of wounds
05/30/2003WO2003043658A1 Anti-proliferative composition
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043651A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/30/2003WO2003043645A1 Compositions comprising organic extracts of geum japonicum thunb var. and the use thereof
05/30/2003WO2003043633A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003WO2003043628A1 Medicament for the treatment of viral skin and tumour diseases
05/30/2003WO2003043625A1 2-aryl-propionic acids and pharmaceutical compositions containing them
05/30/2003WO2003043621A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003WO2003043620A1 A pharmaceutical composition for dermal application
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043597A1 Cosmetic composition derived from morus method for extracting an active principle and resulting active principle
05/30/2003WO2003043591A1 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043572A2 Methods and compositions related to irm compounds and toll-like receptor pathways
05/30/2003WO2003013487A3 Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
05/30/2003WO2003002106A3 Use of tyrosine kinase inhibitions for treating allergic diseases
05/30/2003WO2002096363A3 Method for treating fibrotic diseases or other indications
05/30/2003WO2002078718A3 Compositions, methods and apparatuses for singlet oxygen delivery
05/30/2003WO2002030443A3 Regulation of human skin healing
05/30/2003WO2002016313A3 Integrin receptor inhibitors
05/30/2003WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
05/30/2003CA2467752A1 Piperidin-2-one derivative compounds and pharmaceutical composition comprising the same as active ingredient
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467549A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003CA2467246A1 Composition and method for treatment of wounds
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467053A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003CA2466733A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466072A1 Substituted indolizine-like compounds and methods of use
05/30/2003CA2464867A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/29/2003US20030100772 Oxygen-containing heterocyclic compounds
05/29/2003US20030100608 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/29/2003US20030100603 Administering to the patient subject to a C-reactive protein associated inflammatory condition, an effective amount of a non-alpha-tocopherol enriched tocopherol
05/29/2003US20030100599 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100588 Indole-type inhibitors of p38 kinase
05/29/2003US20030100585 For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )- 3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid
05/29/2003US20030100577 Neurotrophic agents in treatment of solid tumors and vascular disease
05/29/2003US20030100574 Tricyclic 3,4-propinoperhydropurines; uses thereof for blocking neuronal transmission
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100564 Administering 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione and/or metabolite thereof; treating neoplastic diseases, atherosclerosis, restenosis, rheumatoid arthritis, Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis
05/29/2003US20030100548 Antiarthritic agents; atherosclerosis and chronic obstructive pulmonary disease treatments
05/29/2003US20030100538 Substituted chalcones as therapeutic compounds
05/29/2003US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer
05/29/2003US20030100083 Preparation of pseudomonic acid A; obtain bacteria capable of producing pseudomonic acid A, culture, ferment and isolate pseudomonic acid A from culture
05/29/2003US20030099747 Thickened oil compositions of edible oil
05/29/2003US20030099721 Method for improving morbid dermatitis by inhibiting activity of a plasminogen activator in the skin
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers
05/29/2003US20030099678 Method and topical formulation for treating skin conditions associated with aging
05/29/2003US20030099677 Cosmetic composition and method of treating skin
05/29/2003US20030099666 Gum resin as a carrier for topical application of pharmacologically active agents
05/29/2003US20030099661 Compositions and methods for the treatment of immune related diseases
05/29/2003US20030099660 For regenerating tissues; antiaging agents; medical diagnosis; monitoring chemotherapy
05/29/2003US20030099652 Novel human protein tyrosine kinase
05/29/2003US20030099628 Preventing proliferation of a tumor, using heparinase III; use sequencing heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis
05/29/2003US20030099608 Human cytokine receptor
05/28/2003EP1314728A1 Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives
05/28/2003EP1314719A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
05/28/2003EP1314438A1 Anti-proliferative composition
05/28/2003EP1314435A1 Cosmetic and/or dermatologic active substance preparation
05/28/2003EP1314417A1 Hair growers
05/28/2003EP1313857A2 Lipid metabolism molecules
05/28/2003EP1313844A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313768A2 Antisense oligonucleotides against vr1
05/28/2003EP1313737A1 Novel guanidino derivatives as inhibitors of cell adhesion
05/28/2003EP1313726A1 Quinoline derivatives having vegf inhibiting activity
05/28/2003EP1313718A2 Inhibitors of copper-containing amine oxidases
05/28/2003EP1313711A2 Indazole derivatives as jnk inhibitors
05/28/2003EP1313710A1 Pyrazole derivatives and their use as protein kinase inhibitors
05/28/2003EP1313695A1 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
05/28/2003EP1313512A1 Vascular endothelial growth factor 2
05/28/2003EP1313497A1 Use of extracts of the cassia alata plant
05/28/2003EP1313479A1 Hair loss prevention
05/28/2003EP1313461A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
05/28/2003EP1313448A1 Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
05/28/2003EP1313442A2 Storage stable tretinoin and 4-hydroxy anisole containing topical composition
05/28/2003EP1232173B1 Fusidic acid derivatives
05/28/2003EP1206462B1 Heterocyclic compounds inhibiting angiogenesis
05/28/2003EP1169300B1 Compounds derived from benzoic acid esters, composition containing said compounds and use thereof
05/28/2003EP1165115B1 Modulation of vascular permeability by mean of tie2 receptor activators
05/28/2003EP1163239B1 Modified amino-acid amides as cgrp antagonists
05/28/2003EP1146885B1 Pre-conditioning against cell death
05/28/2003EP1143983A4 Spray delivery of cells
05/28/2003EP1039904B1 Synergistic antimicrobial compositions
05/28/2003EP1032415B1 Composition for the treatment of allergic conditions with cysteine and serine proteinase inhibitors
05/28/2003EP0966294B1 Bifurcated method to process aloe whole leaf
05/28/2003EP0966260B1 Oil-in-water emulsions containing a 1,3,5-triazine derivative and a copolyol silicone and cosmetic applications
05/28/2003EP0869781B1 Transdermal device for the delivery of flurbiprofen
05/28/2003EP0859592B1 Skin-care agent for ageing skin
05/28/2003EP0788360B1 Boronic ester and acid compounds, synthesis and uses
05/28/2003EP0748215B1 Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
05/28/2003CN1420933A Method of inducing angiogenesis by micro-organs
05/28/2003CN1420891A Pharmaceutical compound
1 ... 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 ... 1065